Compare AURA & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AURA | BCYC |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.2M | 360.7M |
| IPO Year | 2021 | 2019 |
| Metric | AURA | BCYC |
|---|---|---|
| Price | $6.54 | $5.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $19.00 | $14.00 |
| AVG Volume (30 Days) | 238.6K | ★ 562.4K |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.73 | $4.24 |
| 52 Week High | $7.48 | $9.55 |
| Indicator | AURA | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 57.25 | 51.96 |
| Support Level | $5.83 | $5.03 |
| Resistance Level | $6.73 | $7.14 |
| Average True Range (ATR) | 0.41 | 0.31 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 54.67 | 77.14 |
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.